Variability in market uptake of psychotropic medications in Europe reflects cultural diversity

Table 2 Total use of the case study medications and country scores on Hofstede dimensions

	Total use of the case study medications in DDDs/1000inhabitants/year				Country scores
Country	t = 0	t = 1	t = 2	t = 3	PDI	IDV	MAS	UAI	LTO	IVR
Austria	8.9	52.0	101.6	214.5	11	55	79	70	60	63
Belgium	4.0	253.4	426.6	506.1	65	75	54	94	82	57
Czech Republic	0.5	30.7	53.6	56.5	57	58	57	74	70	29
Denmark	26.8	146.1	232.2	341.2	18	74	16	23	35	70
Estonia	10.9	33.7	52.3	45.7	40	60	30	60	82	16
Finland	2.9	123.5	269.7	452.3	33	63	26	59	38	57
France	46.0	230.9	184.8	239.9	68	71	43	86	63	48
Germany	3.8	133.7	201.9	262.3	35	67	66	65	83	40
Greece	13.9	142.4	332.3	494.9	60	35	57	112	45	50
Hungary	5.1	80.4	118.2	169.8	46	80	88	82	58	31
Ireland	8.8	152.4	254.5	350.7	28	70	68	35	24	65
Italy	6.8	127.4	203.6	262.9	50	76	70	75	61	30
Latvia	2.3	31.2	51.0	48.4	44	70	9	63	69	13
Lithuania	1.2	59.1	101.3	92.7	42	60	19	65	82	16
Luxembourg	11.0	226.1	353.2	455.2	40	60	50	70	64	56
Netherlands	5.4	91.5	138.5	176.1	38	80	14	53	67	68
Poland	0.0	0.4	10.2	19.0	68	60	64	93	38	29
Portugal	3.4	181.4	340.5	440.5	63	27	31	104	28	33
Slovak Republic	3.2	58.2	96.20	140.8	104	52	110	51	77	28
Slovenia	2.5	158.3	282.9	356.3	71	27	19	88	49	48
Spain	41.5	344.2	464.2	562.1	57	51	42	86	48	44
Sweden	0.9	76.5	202.7	336.1	31	71	5	29	53	78
United Kingdom	2.4	78.7	141.7	184.7	35	89	66	35	51	69

PDI power distance, IDV individualism, MAS masculinity, UAI uncertainty avoidance, LTO long-term orientation, IVR indulgence
t = 0: the moment first usage was seen, t = 1: one year after first usage was seen, t = 2: two years after first usage was seen and t = 3: three years after first usage was seen

ISSN: 1472-6963